Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 24/2026 June 14, 2026
- Phase 2 Trial for 61Cu-NU101 vs 18F-Piflufolastat in Metastatic Prostate Cancer June 11, 2026
- UPDATE: Memantine for Neuroendocrine Prostate Cancer, Early Efficacy Signals June 9, 2026
- BRCA-Altered mCSPC Progresses Faster on ARPIs: A Real-World Treatment Gap June 9, 2026
EvoPAR-PR01: Saruparib (AZD5305) Phase III Trial in Metastatic Castration-Sensitive Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxSaruparib (AZD5305), a next-generation PARP1-selective inhibitor, represents a promising evolution in prostate cancer therapy, particularly for metastatic castration-sensitive disease (mCSPC), through the ongoing phase III EvoPAR-PR01 trial. Unlike first-generation PARP inhibitors (PARPi) such as olaparib that target both PARP1 and PARP2, saruparib specifically inhibits and traps PARP1 on DNA damage sites, sparing PARP2 to potentially […]
FDA Clears Phase 2b Trial of Teverelix in Advanced Prostate Cancer Patients at High Cardiovascular Risk
/in Clinical Trial, Metastatic, Phase 2/by MaxA new phase 2b clinical trial has received FDA “study may proceed” clearance for teverelix, a long‑acting GnRH antagonist being evaluated in men with advanced prostate cancer who are at high cardiovascular risk. The trial is designed to test a dose‑optimization regimen of teverelix over a 22‑week treatment period, with the primary goal of confirming […]
Molecular Fingerprints of Aggressive Prostate Cancer: How Spatial Multi‑Omics Could Transform Early Risk Detection
/in Observational/by MaxA study used prostate tissue from patients who had undergone surgery, some of whom later relapsed and some of whom remained cancer-free many years afterward. By comparing these two groups, the research team could define which samples represented aggressive disease and then search for molecular features that consistently separated them from indolent tumors. The original […]
KLS-3021 An Oncolytic Viral Therapy For Prostate Cancer Could Soon Reach Clinical Trial Stage
/in Oncolytic, Preclinical Research/by MaxKLS-3021 represents a promising advancement in oncolytic virus therapy, particularly for prostate cancer, where it has shown potential to address unmet needs in early and locally advanced disease. This recombinant vaccinia virus is engineered to selectively infect and lyse tumor cells while delivering a triple payload of therapeutic genes: PH-20 hyaluronidase to degrade the tumor’s […]
SPR1020: a Promising PARP1-Selective Inhibitor in Advanced Solid Tumors (Including mCRPC)
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxA first-in-human Phase 1/2 trial of SPR1020, a highly selective PARP1 inhibitor, dosed its inaugural patient, igniting hope for patients with advanced solid tumors harboring DNA repair deficiencies. This open-label, multicenter study employs a classic 3+3 dose-escalation design to pinpoint the recommended Phase II dose or maximum tolerated dose, transitioning seamlessly into expansion cohorts tailored […]
Dual-Action Nanomaterial Eradicates Cancer Cells And Spares Healthy Tissue
/in Preclinical Research/by MaxScientists at Oregon State University have pioneered a groundbreaking nanomaterial that selectively annihilates cancer cells by harnessing the tumors’ own hostile chemical environment, while leaving healthy tissues completely unscathed. This innovative approach, detailed in a recent study published in Advanced Functional Materials, represents a major leap in chemodynamic therapy (CDT), an emerging treatment strategy that […]
Phase 1 Trial GTB-5550, a Immunotherapy Targeting B7-H3 in Solid Tumors (Including mCRPC)
/in Clinical Trial, Metastatic, Phase 1/by MaxA new immunotherapy called GTB-5550 targeting B7-H3 on cancer cells has received FDA clearance for its first human trial (expected to start in the first half of 2026), offering fresh hope particularly for advanced prostate cancer patients exhausted by standard treatments. GTB-5550 is a TriKE molecule that binds natural killer (NK) cells from the immune […]
UPDATE: Phase 1 Trial for OP-3136 in mCRPC Started Recruiting
/in Clinical Trial, Metastatic, Phase 1/by MaxThe first-in-human phase 1 trial of OP-3136, a novel orally bioavailable KAT6A/B inhibitor for solid tumors, started recruiting, with the prostate cancer cohort focusing on men with metastatic castration-resistant prostate cancer (mCRPC). This represents a significant expansion of OP-3136 beyond its initial focus on estrogen receptor-positive breast cancer, following encouraging preclinical data presented at AACR […]